Stevens-Johnson syndrome and toxic epidermal necrolysis in children;Síndrome de Stevens-Johnson y necrólisis epidérmica tóxica en los niños

Gaceta Medica de Mexico

Volumn 148, Issue 3, 2012, Pages 265-275

  Sotelo Cruz, Norberto ^a  

^a Hospital Infantil del Estado de Sonora   (Mexico)

Author keywords

Intravenous immunoglobulin; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

ALLOPURINOL; CARBAMAZEPINE; CYTOKINE; FAS LIGAND; HLA B ANTIGEN; IMMUNOGLOBULIN;

AGE; APOPTOSIS; CYTOTOXIC LYMPHOCYTE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG RESPONSE; EYE; GENETIC MARKER; GENETIC SUSCEPTIBILITY; HUMAN; INTESTINE MUCOSA; KERATINOCYTE; MUCOSA; PATHOPHYSIOLOGY; RESPIRATORY TRACT MUCOSA; REVIEW; SKIN DEFECT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; UROGENITAL SYSTEM;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; INFANT; PRACTICE GUIDELINES AS TOPIC; STEVENS-JOHNSON SYNDROME;

EID: 84865075569     PISSN: 00163813     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Steven AM, Johnson FC. A new eruptive fever associates with stomatitis and ophthalmia; report of two cases in children. Am J Dis Child. 1922;24:526-33.
2. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol. 1956;68(11):355-61.
3. Batsuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Rojeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiform. Arch Dermatol. 1993;129:92-6.
4. Roujeau JC, Stern RS. Severe adverse cutaneous reaction to drugs. N Engl J Med. 1994;331(19):1272-85.
5. Prendeville JS. Erythema multiform and Stevens-Johnson syndrome in children. Curr Opin Pediatr. 1991;3:673-7.
6. Forman R, Koren G, Shear NH. Erythema multiform, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Saf. 2002;25(3):965-72.
7. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orph J Rare Dis. 2010;5.39. doi10.1186/1750-1172-5-39.
8. Ball R, Ball LK, Wise RP, Braun MM, Beeler JA, Salive ME. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine events reporting system. Pediatr Infect Dis J. 2001;20(2):219-23.
9. La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis, in association with selective COX-2 inhibitors. Drug Saf. 2005;28(10):917-24.
10. Chan HL. Toxic epidermal necrolysis in Singapore, 1989 through 1993: incidence and antecedent drug exposure. Arch Dermatol. 1995;131(10):1212-3.
11. Saiag P, Caumes E, Chosidow O, Revuz J, Rojeau JC. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol. 1992;26(4): 567-74.
12. Rotunda A, Hirsh RJ, Scheinfeld N, Weinberg JM. Severe cutaneous reaction associated with the use of human immunodeficiency virus medications. Acta Derm Venereol. 2003;83(1):1-9.
13. Aydin F, Cokluk C, Sentruk N, Aydin K, Canturk MT, Turanli AY. Stevens-Johnson syndrome in two patients with cranial irradiation and phenytoin. J Eur Acad Dermatol Venereol. 2006;20(5):588-90.
14. Mandelcorn R, Shear NH. Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus? J Am Acad Dermatol. 2003;48(4):525-9.
15. Zakrewiski JL, Lentini G, Such U, et al. Toxic epidermal necrolysis differential diagnosis of an epidermolitic dermopathy in an hematopoietic stem cell transplant recipient. Bone Marrow Transplant. 2002;30(5): 331-3.
16. Aihara Y, Ito S, Kobayashy Y, Aihara M. Stevens-Johnson syndrome associated with azithromycin, followed by transient reactivation of herpes simplex virus infection. Allergy. 2004;59(1):118.
17. Mulvey JM, Padowitz A, Lindely-Jones M, Nickles R. Mycoplasma pneumoniae associated with Stevens-Johnson syndrome. Anaesth Intensive Care. 2007;35(3):414-7.
18. Del Pozzo-Magana BR, Lazo-Langer A, Carleton B, Castro-Pastrana LI, Rieder MJ. A systematic review of the treatment of drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Popul Ther Clin Parmacol. 2011;18(1):e121-33.
19. Ruiz-Maldonado R. Acute disseminated epidermal necrolysis types 1, 2 and 3, study of sixty cases. J Am Acad Dermatol. 1985;13(4):623-35.
20. Saban J, Pais JR, Rodríguez JL, Boixeda D. Sjögren-like pluriglandular exocrine insufficiency after drug-induced toxic epidermal necrolysis. Postgrad Med J. 1991;67(784):195-7.
21. Chung WH, Hung SI. Genetic markers and danger signals in Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergology International. 2010;59(4):325-32.
22. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome...: ethnicity matters. Pharmacogenomics J. 2006;6(4):256-8.
23. Lonjou C, Borot N, Sekula P, et al. A European study of HLB in Stevens-Johnson syndrome an toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18(2):99-107.
24. Chun WH, Hung SI, Yang YJ, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343-50.
25. Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol. 2002;109(1)155-61.
26. Fritsh PO, Ruiz-Maldonado R. Stevens-Johnson syndrome toxic epidermal necrolysis. In: Freedberg IM, Eisen AZ, Wolf K, eds. Fitzpatrick's dermatology in general medicine. New York: McGraw-Hill; 1999. p. 636.
27. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuropSCAR-study. J Invest Dermatol. 2008;128(1):35-44.
28. Rzany B, Correio O, Kelly JP, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first week of antiepileptic therapy: a case control study. Lancet. 1999;353(9171): 2190-4.
29. Bastuji-Garin S, Fouchard N, Bertocci M, Rojeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity of illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149-53.
30. Wetter DA, Camilleri MJ. Clinical, etiologic and histopathologic features of Stevens-Johnson syndrome during a 8 year period at mayo Clinic. Mayo Clin Proc. 2010;85(2):131-8.
31. Sotelo-Cruz N, Hurtado-Valenzuela J, Rascón-Alcantar A. Síndrome de Stevens-Johnson. Informe de 7 casos. Bol Med Hosp Infant Mex. 2005;62(1):25-32.
32. Wolkenstein P, Chosidow O, Flechet ML, et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis. 1996;35(4): 234-6.
33. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59(8):809-20.
34. Kano Y, Hirahara K, Mitsuyama Y, Takahasi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy. 2007;62(12):1439-44.
35. Beller A, Zaccaria L Kawabata T, Gerber BO, Pichler WJ. CD69 up regulation on T cells and as in vitro marker delayed-type drug hypersensitivity. Allergy. 2008;62(2):181-8.
36. Zawodiank A, Lochmatter P, Yerly D, et al. In vitro detection of cytotoxic T and NK cells in a peripheral blood of patients with various druginduced skin disease. Allergy. 2009;65(3):376-84.
37. Yun SJ, Choi MS, Piao MS, et al. Serum lactate dehydrogenase is a novel marker for the evaluation of disease severity in early stage of toxic epidermal necrolysis. Dermatology. 2008;217(3):254-9.
38. Ramírez-González MD, Herrera-Enríquez M, Villanueva-Rodríguez LG, Castell-Rodríguez AE. Role of epidermal dendritic cells in drug-induced cutaneous adverse reactions. Handb Exp Pharmacol. 2009;188:137-62.
39. Viard L, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282(5388):490-3.
40. Majumdar S, Mockenpaut M, Rojeau J, Twnsed A. Interventions for toxic epidermal necrolysis. Cochrane Database Syst Rev. 2002;4:CD0011435.
41. Mangla K, Rastogi S, Goyal P, Sloanki RB, Rawl RC. Efficacy of low dose intravenous immunoglobulin in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol. 2005;71(6):398-400.
42. Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol. 2002;47(4):548-52.
43. Kühn-Córdova I, Ramírez-Bouchan D, Gamboa-Marrufo JD. Uso de inmunoglobulina intravenosa en el tratamiento de la necrólisis epidérmica tóxica y síndrome de Stevens-Johnson. An Pediatr. 2007;67(1):68-73.
44. Worswik S, Cotliar J. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review treatment options. Dermatologic Therapy. 2011;24(2):207-8.
45. Sotelo-Cruz N. Síndrome de Stevens-Johnson y necrólisis epidérmica tóxica. Revisión de 10 casos. 2-0 Coloquio Internacional de Toxicología Clínica Hospital Juárez, SSA; 21-23 de septiembre, 2011; México, D.F. (datos no publicados).
46. Gregory DG. Treatment of acute Stevens-Johnson syndrome and toxic epidermal necrolysis using amniotic membrane: a review of 10 consecutive cases. Ophthalmology. 2011;118(5):908-14.
47. Spies M, Sanford AP, Aili Low JF, Wolf SE, Herndon DN. Treatment of extensive toxic epidermal necrolysis in children. Pediatrics. 2001;108(5):1162-8.
48. Adzick NS, Kim SH, Bondoc CC, Quinby WC, Remensnyder JP. Management of toxic epidermal necrolysis in a patient a burn center. Am J Dis Child. 1985;139(5):499-502.
49. Khalili B, Bahna S. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol. 2006;97(3):272-80.
50. Ferrándiz-Pulido C, García-Fernández D, Domínguez-Sampedro P, García-Patos V. Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of the experience with pediatrics patients in a university hospital. J Eur Acad Dermatol Venereol. 2011;25(10):1153-9.
51. Finklestein Y, Soon GS, Acuna P, et al. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011;128(4):723-8.